The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future.
Here we describe our efforts to develop a noninvasive blood test for the detection of …

BACKGROUND Since surgical removal remains the only cure for pancreatic cancer, early
detection is of utmost importance. Circulating biomarkers have potential as diagnostic tool …

Background Liquid biopsies enable the detection of circulating tumor DNA (ctDNA).
However, the clinical significance of KRAS-mutated ctDNA for pancreatic cancer has been …

BACKGROUND Cell‐free circulating tumor DNA (ctDNA) in serum has been considered to
be a useful candidate for noninvasive cancer diagnosis. The current study was designed to …

Recent improvements in next-generation sequencing (NGS) technology have enabled
detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue …

The utility of KRAS mutations in plasma circulating cell-free DNA (cfDNA) samples as non-
invasive biomarkers for the detection of pancreatic cancer has never been evaluated in a …

We used KRAS mutations to investigate the clinical relevance of circulating tumor DNA
(ctDNA) measurements in patients with advanced pancreatic cancer. Fifty-three blood …

Serial biopsy of pancreatic ductal adenocarcinoma (PDAC), to chart tumour evolution
presents a significant challenge. We examined the utility of circulating free DNA (cfDNA) as …

Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year
survival of< 10% because of diffuse symptoms leading to late-stage diagnosis. That survival …

Background Many new pancreatic cancer treatment combinations have been discovered in
recent years, yet the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains grim …